share_log

Vivos Therapeutics | 10-Q: Quarterly report

Vivos Therapeutics | 10-Q: Quarterly report

Vivos Therapeutics | 10-Q：季度报表
美股sec公告 ·  05/14 16:22
Moomoo AI 已提取核心信息
Vivos Therapeutics, a medical technology company specializing in treatment alternatives for patients with dentofacial abnormalities and sleep apnea, reported a decrease in revenue for the first quarter of 2024. Total revenue fell by 11% to $3.4 million compared to $3.9 million in the same period of the previous year. This decline was attributed to a $98,000 drop in product revenue and a $340,000 decrease in service revenue. The company's net loss widened to $3.8 million from $1.7 million year-over-year. Operating expenses decreased by 25% to $4.9 million, primarily due to reduced professional fees and personnel costs following a reduction in force. Despite cost-saving measures and reduced cash used in operations, Vivos Therapeutics acknowledged the need for additional financing to sustain operations and comply with Nasdaq's minimum stockholders' equity requirement. The company's cash and cash equivalents stood at $2.6 million as of March 31, 2024. Vivos Therapeutics continues to implement a remediation plan to address material weaknesses in internal control over financial reporting, with progress expected throughout 2024.
Vivos Therapeutics, a medical technology company specializing in treatment alternatives for patients with dentofacial abnormalities and sleep apnea, reported a decrease in revenue for the first quarter of 2024. Total revenue fell by 11% to $3.4 million compared to $3.9 million in the same period of the previous year. This decline was attributed to a $98,000 drop in product revenue and a $340,000 decrease in service revenue. The company's net loss widened to $3.8 million from $1.7 million year-over-year. Operating expenses decreased by 25% to $4.9 million, primarily due to reduced professional fees and personnel costs following a reduction in force. Despite cost-saving measures and reduced cash used in operations, Vivos Therapeutics acknowledged the need for additional financing to sustain operations and comply with Nasdaq's minimum stockholders' equity requirement. The company's cash and cash equivalents stood at $2.6 million as of March 31, 2024. Vivos Therapeutics continues to implement a remediation plan to address material weaknesses in internal control over financial reporting, with progress expected throughout 2024.
专门为牙面异常和睡眠呼吸暂停患者提供替代治疗的医疗技术公司Vivos Therapeutics报告称，2024年第一季度的收入有所下降。与去年同期的390万美元相比，总收入下降了11％，至340万美元。这种下降归因于产品收入下降了98,000美元，服务收入减少了34万美元。该公司的净亏损从同比的170万美元扩大至380万美元。运营支出下降了25％，至490万美元，这主要是由于削减后专业费用和人员成本减少。尽管采取了节省成本的措施并减少了运营中使用的现金，但Vivos Therapeutics承认需要额外的融资来维持运营并遵守纳斯达克的最低股东权益要求。截至2024年3月31日，该公司的现金及现金等价物为260万美元。Vivos Therapeutics继续实施补救计划，以解决财务报告内部控制方面的重大缺陷，预计将在2024年全年取得进展。
专门为牙面异常和睡眠呼吸暂停患者提供替代治疗的医疗技术公司Vivos Therapeutics报告称，2024年第一季度的收入有所下降。与去年同期的390万美元相比，总收入下降了11％，至340万美元。这种下降归因于产品收入下降了98,000美元，服务收入减少了34万美元。该公司的净亏损从同比的170万美元扩大至380万美元。运营支出下降了25％，至490万美元，这主要是由于削减后专业费用和人员成本减少。尽管采取了节省成本的措施并减少了运营中使用的现金，但Vivos Therapeutics承认需要额外的融资来维持运营并遵守纳斯达克的最低股东权益要求。截至2024年3月31日，该公司的现金及现金等价物为260万美元。Vivos Therapeutics继续实施补救计划，以解决财务报告内部控制方面的重大缺陷，预计将在2024年全年取得进展。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

独立文件4  查看翻译

独立文件5  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息